🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchOrforglipron ATTAIN-4 — looking for input Page 3

Orforglipron ATTAIN-4 — looking for input

LabKate Sat, Feb 7, 2026 at 2:59 PM 14 replies 1,111 viewsPage 3 of 3
JennaRN
Senior Member
1,987
8,923
Mar 2024
Colorado
Online
Feb 12, 2026 at 5:03 AM#11
paige_pharma said:
Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then…

No disagreement, though the timescale matters more than the mechanism here. Most of what looks like a difference in kind turns out to be a difference in how long somebody waited.

4 2Dr.KarenChen, Dr.NateNeph, PharmD_Rodriguez and 1 other
Reply Quote Save Share Report
LeilaHI
Member
167
789
Jan 2025
Honolulu, HI
Feb 12, 2026 at 8:50 AM#12
Dr.MetabolicMD said:
Orforglipron is a small molecule rather than a peptide, which is the whole point: no SNAC absorption enhancer, no fasting window, no cold chain, and…

Genuinely useful, thank you. I had the facts and not the framework. Printing the relevant bit and taking it with me.

5 3VendorMark, COA_Karl, MikeFit_NJ and 2 others
Reply Quote Save Share Report
CryptoCarl
Member
789
3,456
May 2024
Arizona
Feb 12, 2026 at 12:37 PM#13
paige_pharma said:
Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then…

I do not accept the framing. The question has been narrowed to the version that has a tidy answer, and the part that was dropped is the part the OP actually asked about.

6 4AussieAnna, BethLabQueen, ChrisMacros and 3 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
lucas_SP_BR
Member
456
1,890
Jun 2024
São Paulo, BR
Feb 12, 2026 at 4:24 PM#14

The figures, for anyone assembling their own picture. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.

7 5KarenAZ_mom, zoe_NC, Dr.ObesityLA and 4 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Feb 12, 2026 at 8:11 PM#15

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Report rather than reply if it drifts again.

Last edited: Feb 12, 2026 at 10:11 PM
8 6PurityPaulOR, MaxMetOK, MounjBrad and 5 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register